直接口服抗凝药处方:关注证据缺口
本文综述直接口服抗凝药(DOAC)在非瓣膜性房颤等适应症中的许可证据局限性,指出关键试验对老年人、女性、肥胖患者及非欧洲裔人群代表性不足;通过四个临床案例探讨处方挑战,提示处方者需认识证据缺口对临床实践的不利影响。
要点
- DOAC关键试验对老年人、女性、肥胖及非欧洲裔人群代表性不足
- 处方者常依赖产品特性摘要,可能忽视证据局限性
- 临床案例揭示上述人群处方DOAC的挑战与风险
核心结论
- DOAC许可证据在老年人、女性、肥胖患者及非欧洲裔人群中存在代表性不足的缺口,可能影响临床处方决策。
研究设计与样本
- 综述性文章,通过四个临床案例探讨DOAC处方挑战。
主要发现
- 关键试验对老年人、女性、肥胖患者及非欧洲裔 ethnic backgrounds 人群代表性不足。
- 处方者可能未意识到这些试验局限性对临床实践的不利影响。
临床怎么用
- 处方DOAC时应关注患者是否属于关键试验中代表性不足的人群,并权衡证据缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation, amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC's market authorisation. However, prescribers may not be aware of the limitations within these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using four clinical vignettes that explore prescribing challenges in older adults, female patients, patients with obesity and patients from non-Europid ethnic backgrounds.
引用
- Adeyeye E, Maniero C, Magavern EF, et al. Prescribing direct-acting oral anticoagulants - Mind the evidence gap. Br J Clin Pharmacol. 2022. PMID: 35771028. doi:10.1111/bcp.15450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。